Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Cedars-Sinai Phase I-II clinical trial may help combat recurrence of small cell lung cancer

Alain C. Mita, MD, is fighting an uphill battle against small cell lung cancer. Despite the severity of the disease, the standard-of-care treatment remains the same today as it was nearly 30 years ago.

14 Nov 2013

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

EKF Diagnostics, the global diagnostics business, announces that EKF Molecular Diagnostics will launch four new PointMan DNA enrichment kits.

From EKF Diagnostics 13 Nov 2013

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics biotechnologies GmbH and Roche today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.

13 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Walter Quan, Jr., MD Chief of Medical Oncology and Director of Immunotherapy at Cancer Treatment Centers of America- Western Regional Medical Center is presenting new findings that are showing a major benefit to cancer patients.

11 Nov 2013

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide. Current therapies that target cellular kinases have been effective for some patients: however, many individuals with NSCLS do not respond.

11 Nov 2013

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the start of clinical testing with its EGFR-targeting ADC, IMGN289.

6 Nov 2013

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.

5 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

FDG-PET parameter predicts locally advanced lung cancer survival

High post-treatment concentrations of a radioactive imaging marker are predictive of worse overall survival from inoperable, locally advanced non-small-cell lung cancer, prospective study findings suggest.

31 Oct 2013

DNA methylation signature marks recurrence in early stage lung cancer

An international research team has identified a DNA methylation signature that identifies patients with stage I non-small-cell lung cancer who are at high risk for relapse.

31 Oct 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Edward Garon, Director of Thoracic Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, at the 15th World Conference on Lung Cancer in Sydney, Australia (Abstract #2416).

31 Oct 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

EZH2 protein may aid prognostication in resected NSCLC

A protein called “enhancer of zeste homolog-2” is frequently expressed in non-small-cell lung cancer and may have prognostic value following surgical resection, US researchers believe.

30 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Current drugs may harbor small-cell lung cancer promise

Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease.

28 Oct 2013

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced additional data from the Phase III clinical trial for its serum protein test, VeriStrat. Results were presented at the 15th World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

24 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

Small Cell Lung Cancer News and Research

Cedars-Sinai Phase I-II clinical trial may help combat recurrence of small cell lung cancer

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

immatics, Roche enter into cancer vaccine and immunotherapy deal

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Study suggests that therapies targeting KDM2A may benefit subset of NSCLS patients

ImmunoGen starts clinical testing with its EGFR-targeting ADC, IMGN289 for several types of cancers

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Experimental drug effective in treating patients with non-small cell lung cancer

FDG-PET parameter predicts locally advanced lung cancer survival

DNA methylation signature marks recurrence in early stage lung cancer

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

EZH2 protein may aid prognostication in resected NSCLC

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Current drugs may harbor small-cell lung cancer promise

Biodesix presents additional VeriStrat Phase III trial data at World Conference on Lung Cancer

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News